Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EPS (Basic) (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed EPS (Basic) for 12 consecutive years, with -$1.39 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 334.37% to -$1.39 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.19 through Dec 2025, down 219.0% year-over-year, with the annual reading at -$3.19 for FY2025, 215.84% down from the prior year.
  • EPS (Basic) hit -$1.39 in Q4 2025 for Viking Therapeutics, down from -$0.81 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.16 in Q4 2021 to a low of -$1.39 in Q4 2025.
  • Historically, EPS (Basic) has averaged -$0.34 across 5 years, with a median of -$0.23 in 2022.
  • Biggest five-year swings in EPS (Basic): rose 17.39% in 2023 and later tumbled 334.37% in 2025.
  • Year by year, EPS (Basic) stood at -$0.16 in 2021, then plummeted by 62.5% to -$0.26 in 2022, then grew by 3.85% to -$0.25 in 2023, then fell by 28.0% to -$0.32 in 2024, then crashed by 334.37% to -$1.39 in 2025.
  • Business Quant data shows EPS (Basic) for VKTX at -$1.39 in Q4 2025, -$0.81 in Q3 2025, and -$0.58 in Q2 2025.